This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
GNC Holdings Grapples With Margin Weakness, Stiff Competition
by Zacks Equity Research
Weak margins, declining year-over-year revenues and rising operating costs continue to pose challenges to GNC Holdings (GNC).
Stryker Gains Ground on MAKO Robotic Unit Amid Forex Woes
by Zacks Equity Research
Solid performance by the MAKO robotic platform has been boosting Stryker's (SYK) revenues for long.
LabCorp's Covance Business Bounces Back on Chiltern Buyout
by Zacks Equity Research
Despite a dull show for several quarters, LabCorp's (LH) Covance Drug Development reported strong growth in the third quarter, courtesy of Chiltern acquisition. However, volume woes remain.
Align Technology (ALGN) Grows on InvisAlign System Strength
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strength in the InvisAlign space.
Edwards Lifesciences' Pipeline Strong Amid Rising Expenses
by Zacks Equity Research
Edwards Lifesciences' (EW) aim at building its pipeline to fortify foothold across all operating businesses augurs well for the company. However, higher operating expenses are a concern.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
Patterson Companies Dental Business Dull, Competition Rife
by Zacks Equity Research
Patterson's (PDCO) dental segment sales have been weak. The company faces stiff competition from at least 15 full-service distributors and small distributors.
Hologic (HOLX) Focuses on Breast Health, Ties Up with Clarius
by Zacks Equity Research
Hologic (HOLX) forges ahead with its efforts to strengthen hold in the high potential breast cancer screening market.
Hologic's FDA Nod for Quantra Software Boosts Breast Health
by Zacks Equity Research
Hologic (HOLX) is consistently trying to boost its Breast Health segment.
5 MedTech Stocks to Beat Tax Hazards With Positive Returns
by Zacks Equity Research
Trump's tax reform policies promise to cut corporate taxes. However, the future of the U.S. MedTech industry depends on the much-awaited decision on the 2.3% medical device tax.